Rhythm Pharmaceuticals to Disclose Preliminary Data from PWS Trial on December 11
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 10 2025
0mins
Source: Globenewswire
- Clinical Trial Update: Rhythm Pharmaceuticals will host a conference call on December 11 at 8:00 a.m. ET to disclose preliminary data from its exploratory Phase 2 trial of setmelanotide in patients with Prader-Willi syndrome, which is expected to provide significant support for the company's market positioning in rare neuroendocrine diseases.
- Investor Engagement: The conference will be available via webcast, requiring participants to register ten minutes in advance, demonstrating the company's commitment to transparency and investor communication aimed at boosting market confidence.
- Product Background: Setmelanotide is Rhythm's lead asset, already FDA-approved for obesity treatment associated with Bardet-Biedl syndrome, and the upcoming data is anticipated to further propel its application in other rare diseases.
- Future Outlook: Rhythm is advancing the clinical development of setmelanotide in other rare diseases, and the data release is expected to lay the groundwork for future regulatory submissions and market expansion.
Analyst Views on RYTM
Wall Street analysts forecast RYTM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RYTM is 140.62 USD with a low forecast of 123.00 USD and a high forecast of 167.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Analyst Rating
14 Buy
1 Hold
0 Sell
Strong Buy
Current: 105.950
Low
123.00
Averages
140.62
High
167.00
Current: 105.950
Low
123.00
Averages
140.62
High
167.00
About RYTM
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE, as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. IMCIVREE is approved by the Food and Drug Administration (FDA) for chronic weight management in adult and pediatric patients six years of age and older with monogenic or syndromic obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor (LEPR) deficiency as determined by an FDA-approved test demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS). In addition to setmelanotide, it has two earlier-stage investigational MC4R agonists in clinical development, RM-718, designed for weekly administration, and bivamelagon, an oral small molecule.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
